This site is intended for healthcare professionals

Health Canada approves first-ever gene replacement therapy, Luxturna, a one time treatment for vision loss due to inherited retinal dystrophy with biallelic RPE65 mutations.-Novartis

Read time: 1 mins
Last updated:16th Mar 2021
Published:22nd Oct 2020
Condition: Retinal Dystrophy
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest